Cardio Diagnostics Holdings (NASDAQ: CDIO) is taking its cardiovascular risk assessment solutions directly to the employer benefits market, participating in four national benefits conferences in June to discuss strategies for earlier identification of heart disease risk and cost management. The company's efforts come as cardiovascular disease remains one of the most expensive health conditions in the United States, accounting for approximately 11% of all U.S. healthcare expenditures in 2020–2021, according to the American Heart Association.
A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient's health, affecting employers, insurers, and healthcare systems through higher medical costs, lost productivity, and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for employee benefits are seeking new strategies to identify risk earlier and improve outcomes.
Cardio Diagnostics has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. By engaging directly with benefits decision-makers at these conferences, the company aims to demonstrate how its technology can help employers tackle cardiovascular risk and contain healthcare costs.
The conferences provide a platform for Cardio Diagnostics to discuss innovative approaches to cardiovascular disease prevention, risk assessment, and cost management with stakeholders who are increasingly focused on value-based care and population health management. The company's participation underscores a growing recognition that proactive cardiovascular risk assessment can yield significant savings for employers and improve employee health outcomes.
According to the full terms of use and disclaimers on the InvestorBrandNetwork website, the latest news and updates relating to CDIO are available in the company's newsroom at https://ibn.fm/CDIO.
